非小细胞肺癌市场规模、份额、成长分析、按类型、按治疗方法、按最终用途行业、按地区 - 行业预测，2025-2032 年

2023年非小细胞肺癌市场规模为269.4亿美元，从2024年的306.8亿美元成长到2032年的869.4亿美元，在预测期内（2025-2032年）预计将以复合年增长率增长。 。

将免疫查核点抑制剂（ICIs）引入一线治疗显着推动了非小细胞肺癌（NSCLC）领域的市场收益成长。非小细胞肺癌（NSCLC）占全球肺癌患者的 80-85%，其盛行率促使主要企业专注于开发创新治疗方法并提高现有选择的有效性。这种增长也支持了肺癌作为全球癌症相关死亡主要原因的声誉。非小细胞肺癌诊断数量的增加，加上已开发国家和新兴国家社会意识的提高，进一步放大了市场活力。此外，主要市场参与者承诺将非小细胞肺癌治疗纳入其产品线以及研发投资的增加也是推动全球市场扩张的关键因素。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管环境
• 案例研究
• 技术进步

非小细胞肺癌市场规模：依类型

• 市场概况
• 腺癌
• 鳞状细胞癌
• 大细胞癌
• 大细胞神经内分泌肿瘤

非小细胞肺癌市场规模：依治疗方法

• 市场概况
• 化疗
• 标靶治疗
  • Bevacizumab
  • 奈西妥尤单抗
  • Ramucirumab
• 免疫疗法
  • 纳武单抗
  • Atezolizumab
• 其他的

非小细胞肺癌市场规模：依最终用途产业

• 市场概况
• 医院
• 居家护理
• 专科诊所
• 其他的

非小细胞肺癌市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• AstraZeneca（United Kingdom）
• Bristol-Myers Squibb Company（United States）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Bayer AG（Germany）
• Eli Lilly and Company（United States）
• GlaxoSmithKline plc（United Kingdom）
• Sanofi（France）
• AbbVie Inc.（United States）
• Johnson & Johnson（United States）
• Gilead Sciences, Inc.（United States）
• Amgen Inc.（United States）
• Boehringer Ingelheim GmbH（Germany）
• Daiichi Sankyo Company, Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Biogen Inc.（United States）
• Regeneron Pharmaceuticals, Inc.（United States）

结论和建议

Non-Small Cell Lung Cancer Market size was valued at USD 26.94 Billion in 2023 and is poised to grow from USD 30.68 Billion in 2024 to USD 86.94 Billion by 2032, growing at a CAGR of 13.9% during the forecast period (2025-2032).

The introduction of immune checkpoint inhibitors (ICIs) for first-line treatment is significantly propelling market revenue growth in the non-small cell lung cancer (NSCLC) sector. Representing 80-85% of lung cancer cases globally, NSCLC's prevalence has prompted leading companies to focus on developing innovative therapies and enhancing the efficacy of existing options. This growth is also driven by lung cancer's reputation as a leading cause of cancer-related deaths worldwide. Rising diagnoses of NSCLC, coupled with increased public awareness in both developed and developing countries, are further amplifying market dynamics. Additionally, the commitment of major market players to incorporate NSCLC medications into their pipelines and their heightened investment in research and development are crucial factors driving the expansion of the global market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Non-Small Cell Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Non-Small Cell Lung Cancer Market Segmental Analysis

Global Non-Small Cell Lung Cancer Market is segmented by type, treatment, end-use industry and region. Based on type, the market is segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma and large cell neuroendocrine tumors. Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Based on end-use industry, the market is segmented into hospitals, homecare, specialty clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Non-Small Cell Lung Cancer Market

The Non-Small Cell Lung Cancer (NSCLC) market is primarily driven by the escalating incidence of lung cancer attributed to factors such as smoking, air pollution, and increased vulnerability due to HIV infection, alongside a growing population. Additionally, the market is expected to expand with the rising number of regulatory approvals for innovative therapies tailored to NSCLC. Key industry players are prioritizing research and development investments to address the surging demand for effective treatment options. This combination of increasing disease prevalence and advancements in drug approvals is poised to significantly enhance the growth trajectory of the NSCLC market in the upcoming years.

Restraints in the Non-Small Cell Lung Cancer Market

A significant challenge facing the non-small cell lung cancer market is the high cost associated with its treatment options. While effective therapies such as chemotherapy, surgery, targeted therapies, radiation, and immunotherapy are available, they come with substantial financial burdens. This expensive nature of treatment poses a barrier to accessing care, limiting affordability for many patients and ultimately restricting market growth. Consequently, the financial implications of these therapies can hinder the overall advancement of the non-small cell lung cancer market, making it difficult for a broader population to benefit from available treatment options.

Market Trends of the Non-Small Cell Lung Cancer Market

The non-small cell lung cancer (NSCLC) market is witnessing significant growth, driven by a rise in diagnoses and heightened awareness across global regions, both developed and developing. Innovative treatment options, including targeted therapies and immunotherapies, are being actively developed by leading pharmaceutical companies, expanding their portfolios. Increased investment in research and development from major players is enhancing treatment availability and efficacy, further stimulating market momentum. Additionally, supportive regulatory frameworks and healthcare initiatives are improving patient access to advanced therapies, positioning the NSCLC market for sustained growth in the coming years as it aligns with evolving medical needs and technological advancements.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Non-Small Cell Lung Cancer Market Size by Type & CAGR (2025-2032)

• Market Overview
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Large Cell Neuroendocrine Tumors

Global Non-Small Cell Lung Cancer Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted Therapy
  • Bevacizumab
  • Necitumumab
  • Ramucirumab
• Immunotherapy
  • Nivolumab
  • Atezolizumab
• Others

Global Non-Small Cell Lung Cancer Market Size by End-Use Industry & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Non-Small Cell Lung Cancer Market Size & CAGR (2025-2032)

• North America (Type, Treatment, End-Use Industry)
  • US
  • Canada
• Europe (Type, Treatment, End-Use Industry)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End-Use Industry)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End-Use Industry)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End-Use Industry)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations